Conduit Pharmaceuticals 3/28/2025 Earnings Report

Conduit Pharmaceuticals EPS Results

• Actual EPS: -$304.95
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Conduit Pharmaceuticals Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Conduit Pharmaceuticals Announcement Details

• Date: 3/28/2025
• Time: After Market Closes
• Conference Call Date: N/A
• Conference Call Time: N/A

Conduit Pharmaceuticals (NASDAQ:CDT) (NASDAQ:CDT) is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation antibody therapeutics. The company’s research platform leverages proprietary antibody engineering to design highly specific molecules that target key signalling pathways in oncology and immunology. Headquartered in Seattle, Washington, Conduit operates research and development facilities in both the United States and Europe, positioning it to advance global clinical programs and partnerships.

The Conduit pipeline includes multiple product candidates in various stages of clinical and preclinical development. CDX-3379 is a monoclonal antibody targeting HER3, being evaluated in head and neck squamous cell carcinoma and other solid tumors. CDX-0159, a novel c-Kit inhibitor, is designed to modulate mast-cell activity in allergic and inflammatory diseases. In parallel, CDX-527 is a bispecific antibody engaging PD-L1 and CD27 to enhance T-cell mediated anti-tumor responses. Each program reflects Conduit’s emphasis on differentiated mechanisms of action and potential combination strategies with existing standard-of-care treatments.

Founded in 2016, Conduit has built a robust translational research engine that integrates structure-based design, in vivo pharmacology and translational biomarkers. The company has established collaborative agreements with academic centers and biopharma partners to accelerate its clinical studies across North America and Europe. Conduit’s approach emphasizes adaptive trial designs and biomarker-driven patient selection to streamline development timelines and improve the probability of clinical success.

Conduit’s leadership team brings deep expertise from top biotechnology and pharmaceutical organizations. The executive management comprises drug development veterans with backgrounds in antibody engineering, clinical oncology and regulatory affairs. Supported by a board of directors with extensive experience in life-science investing and corporate strategy, Conduit is positioned to advance its novel antibody portfolio toward potential regulatory milestones and commercialization.